rts logo

Adma Biologics Inc (ADMA) Stock Could Soon Reward Patient Investors

Adma Biologics Inc (NASDAQ: ADMA) is 164.60% higher on its value in year-to-date trading and has touched a low of $3.06 and a high of $11.90 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADMA stock was last observed hovering at around $11.64 in the last trading session, with the day’s gains setting it 0.32%.

Currently trading at $11.96, the stock is 9.39% and 26.35% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.92 million and changing 2.75% at the moment leaves the stock 102.60% off its SMA200. ADMA registered 231.30% gain for a year compared to 6-month gain of 171.82%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The stock witnessed a 13.04% loss in the last 1 month and extending the period to 3 months gives it a 92.28%, and is 3.55% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.49% over the week and 3.05% over the month.

Adma Biologics Inc (ADMA) has around 624 employees, a market worth around $2.77B and $283.18M in sales. Fwd P/E is 22.15. Profit margin for the company is -1.29%. Distance from 52-week low is 290.85% and 0.50% from its 52-week high. The company has generated returns on investments over the last 12 months (-1.24%).

with sales reaching $86.41M over the same period.The EPS is expected to grow by 371.15% this year, but quarterly earnings will post 38.50% year-over-year. Quarterly sales are estimated to grow 43.70% in year-over-year returns.

Adma Biologics Inc (ADMA) Top Institutional Holders

The shares outstanding are 226.06M, and float is at 223.89M with Short Float at 4.22%.

Adma Biologics Inc (ADMA) Insider Activity

The most recent transaction is an insider sale by Grossman Adam S,the company’sPresident,CEO, and Interim CFO. SEC filings show that Grossman Adam S sold 100,000 shares of the company’s common stock on Jun 14 ’24 at a price of $10.72 per share for a total of $1.07 million. Following the sale, the insider now owns 2.08 million shares.

Adma Biologics Inc disclosed in a document filed with the SEC on Mar 19 ’24 that ELMS STEVE (Director) sold a total of 411,829 shares of the company’s common stock. The trade occurred on Mar 19 ’24 and was made at $6.08 per share for $2.5 million. Following the transaction, the insider now directly holds 2.12 million shares of the ADMA stock.

Still, SEC filings show that on Mar 18 ’24, ELMS STEVE (Director) disposed off 49,887 shares at an average price of $6.01 for $0.3 million. The insider now directly holds 2,527,500 shares of Adma Biologics Inc (ADMA).

Related Posts